Abstract: The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R? is an -A1-Cy1 group, or R is an -A1-Cy1 group and R? is an R1 group, R1 particularly being H or (C1-C6)alkyl group; A1 being an —NH— radical or —NH—CH2— radical; Cy1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Abstract: A mixing tube with multiple shapes is provided, allowing additional injection of gas in order to keep the flow detached from the second shape in an ascent phase and to bring about, in a descent phase, a controlled detachment as a result of the change of slope between the two shapes. A propulsion nozzle for an engine of a spacecraft or aircraft is provided including such a mixing tube and a method for controlling the speed transition of the propulsion gases in such a nozzle in accordance with the altitude. Also, a method is provided for vectorising the thrust in such a nozzle by radial and asymmetrical injection of gas and a control method which prevents re-attachment of the jet to the second shape of such a propulsion nozzle for an engine of a spacecraft when it is in the take-off or landing phase.

Abstract: The present invention concerns a compound having the following formula (I): as well as its use as a medicament, especially for its use for treating viral infections.

Abstract: A method of manufacturing by magnetron cathode sputtering an electrolyte film for use in solid oxide cells (SOC). This method comprises the steps consisting of heating a substrate to a temperature ranging from 200° C. to 1200° C.; followed by subjecting the substrate to at least two treatment cycles, each treatment cycle comprising: 1) depositing one layer of a metal precursor on the substrate by magnetron cathode sputtering of a target made up of the metal precursor, the sputtering being carried out under elemental sputtering conditions; followed by 2) oxidation-crystallisation of the metal precursor forming the layer deposited on the substrate in the presence of oxygen to obtain the transformation of the metal precursor into the electrolyte material; and in that the substrate is kept at a temperature ranging from 200° C. to 1200° C. for the entire duration of each treatment cycle.

Abstract: The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

Abstract: An etching method includes: a physical adsorption process of physically adsorbing an adsorbate based on a first processing gas on a film to be etched under a condition that the pressure of the first processing gas is smaller than the saturated vapor pressure of the first processing gas with respect to a temperature of an object to be processed while cooling the object to be processed on which the film to be etched is formed; and an etching process of etching the film to be etched by reacting the adsorbate with the film to be etched by a plasma of a second processing gas.

Abstract: Disclosed is a method for electrical supply of an apparatus by a system including an intermittent electrical source, electrical storage unit, a fuel cell, and an electrochemical unit for generating the fuel. The method includes steps of: determining a power balance of the system depending on the power consumed by the apparatus and supplied by the intermittent electrical source; receiving data representative of the stability of the power balance during a safety period; controlling the fuel cell and the electrochemical unit: to activate the electrochemical unit if the power balance is greater than a first threshold and the data are not characteristic of a subsequent decrease in the power balance; activating the fuel cell if the power balance is less than a second threshold, which is less than the first threshold, and the data are not characteristic of a subsequent increase in the power balance.

Abstract: The invention describes a device (10) for dispensing microbubbles (30) for cell sonoporation, comprising: a tube configured to receive a vial (20) containing a solution (26) of microbubbles (30), at least two catheters (11, 12) arranged inside the tube and opening into the vial (20) when the latter is received by the tube, wherein, when the first catheter (11) is connected to a first air injection source, air can be injected into the vial (20) via the first catheter so as to generate an overpressure therein, the microbubbles (30) contained in the vial (20) entering the second catheter (12) and moving toward its second end (122). The invention also relates to a sonoporation device, a sonoporation process and a computer program product.

Abstract: A plasma etching method includes a physisorption step for causing an adsorbate that is based on first processing gas to be physisorbed onto a film to be etched, while cooling an object to be processed on which the film to be etched is provided; and an etching step for etching the film to be etched by causing the adsorbate to react with the film to be etched, using the plasma of second processing gas.

Abstract: Disclosed is a method for calculating a control setpoint of a hybrid powertrain of a motor vehicle, the hybrid powertrain including an electric motor and an internal combustion engine (ICE) that is equipped with a gearbox and that is supplied with fuel. The method includes: acquiring a value relative to a power requested at the vehicle's drive wheels; and determining the contribution of the electric motor and the ICE in order to satisfy the request for power at the drive wheels. The determination step involves calculating a triplet of three values, one value relating to the electromechanical power that the electric motor must provide, one value relating to the thermomechanical power that the ICE must provide and one value relating to the ratio that needs to be engaged in the gearbox, this triplet minimising the fuel consumption of the ICE and the current consumption of the electric motor.

Abstract: The present invention relates to the use, as a fluorescent chromophore, of a compound with formula (I) wherein: A1 is —N— or —C(Y1)—; A2 is —N— or —C(Y2)—; A3 is —N— or —C(Y3)—; A4 is —N— or —C(Y4)—; at least one of A1, A2, A3 and A4 representing —N—; X1 is —N— or —C(Y5)—; X2 is —N— or —C(Y6)—; X3 is —N— or —C(Y7)—; and Y1, Y2, Y3, Y4, Y5, Y6 and Y7 are in particular chosen independently of one another from the group made up of: H, electron-donor groups and electron-attracting groups.

Abstract: The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.

Abstract: A method of an embodiment includes (i) a step of supplying a first gas to a chamber, wherein the first gas is perfiuorotetraglyme gas, and (ii) a step of generating plasma of a second gas for etching of a porous film in order to etch the porous film at the same time as the step of supplying a first gas or after the step of supplying a first gas. Partial pressure of the first gas in the chamber or pressure of the first gas in the chamber when only the first gas is supplied to the chamber is higher than critical pressure causing capillary condensation of the first gas in the porous film and is lower than saturated vapor pressure of the first gas at a temperature of the workpiece during execution of the step of supplying a first gas.

Abstract: A plasma etching method includes a physisorption step for causing an adsorbate that is based on first processing gas to be physisorbed onto a film to be etched, while cooling an object to be processed on which the film to be etched is provided; and an etching step for etching the film to be etched by causing the adsorbate to react with the film to be etched, using the plasma of second processing gas.

Abstract: The present invention relates to compounds of the following formula (I), wherein: m represents an integer being equal to 0, 1, 2, 3, 4, 5 or 6, X represents a simple bond or a radical —CHR1 wherein R1 represents:—a hydrogen atom, or—a linear or branched, possibly interrupted by up to 3 heteroatoms selected from O, S or N and/or possibly substituted, (C1-C12)-alkyl, R2, R3 and R4 represent independently from each other:—a hydrogen atom, or—a linear or branched (C1-C12-alkyl or (C1-C12)-acyl R5 represents:—a hydrogen atom, or—a linear or branched, possibly substituted, (C1-C13)-alkyi possibly substituted and possibly interrupted by up to 3 heteroatoms selected from O, S or N, R6 represents:—a hydrogen atom, or—a linear or branched possibly substituted (C1-C12)-alkyl, possibly substituted and possibly interrupted by up to 3 heteroatoms selected from O, S or N, for their use as antibacterial drugs for the treatment and/or the prevention of infection(s) caused by biofilm-forming bacteria.

Abstract: The present invention relates to a complex comprising at least one lanthanide (Ln) and at least one compound (C) comprising a unit of formula (I) below: said unit of formula (I) being covalently connected to at least one antenna which absorbs at a wavelength ranging from 500 nm to 900 nm.

Abstract: The invention relates to a method (S) for generating a plurality of cold-plasma jets at atmospheric pressure in order to treat a target (2), wherein said method includes the following steps: producing (S1) a primary cold-plasma jet (3) at atmospheric pressure using a plasma source (10); placing (S2) a substrate (20, 21, 30, 32, 34) near the target (2) to be treated, said substrate (20, 21, 30, 32, 34) including at least two through-holes; and passing (S3) the plasma through the through-holes (22) of the substrate (20) such as to generate at least two secondary cold-plasma jets (4) at atmospheric pressure.

Abstract: The present invention provides nine selective c-FLIP inhibitors that are useful in the treatment of cancer, alone or in combination with other chemotherapeutic agents, in particular with TRAIL-based chemotherapeutic agents. The present invention also relates to pharmaceutical compositions and kits comprising at least one of the nine selective c-FLIP inhibitors and their use in methods for the treatment of cancer, in particular to overcome chemoresistance or to improve sensitivity of tumors to TRAIL-based therapy.

Abstract: The present invention relates to compounds of the following general formula (I): wherein: R1 is notably a group —NRaRb, Ra and Rb forming together with the nitrogen atom onto which they are bound, a heterocycle comprising from 5 to 30 atoms, R2 is notably an aryl comprising from 5 to 30 atoms, and R3 is notably an alkenyl comprising from 1 to 20 carbon atoms.

Abstract: The invention concerns a compound formed by functionalized micro- or nanoparticles associated covalently with rheology-modifying polymers. The invention is characterized in that the functionalized micro- or nanoparticles are functionalized micro- or nanoparticles of cerium oxide (CeO2) having a nominal diameter of between 1 and 1500 nm. The rheology-adapting or -modifying polymers are selected from among non-associative or associative polymers. The invention is used in skin protection or decontamination.